The immunoglobulin superfamily member 6 (IGSF6), also known as DORA, is a cell surface protein predominantly expressed in immune cells, particularly in T lymphocytes and dendritic cells. Structurally, it contains a single immunoglobulin (Ig) domain and a transmembrane region, suggesting roles in cell-cell interactions and immune regulation. While its precise biological function remains under investigation, IGSF6 has been implicated in modulating T-cell activation and differentiation. Studies suggest it may act as a co-inhibitory receptor, influencing immune synapse formation and cytokine production.
IGSF6 antibodies are primarily utilized as research tools to explore the protein's expression patterns, functional mechanisms, and involvement in immune-related diseases. Commercially available antibodies (e.g., monoclonal or polyclonal) enable detection via techniques like flow cytometry, immunohistochemistry, and Western blotting. Recent research highlights potential links between IGSF6 dysregulation and autoimmune disorders, chronic inflammation, and cancer progression, sparking interest in its therapeutic targeting. For instance, IGSF6 overexpression in certain tumors may contribute to immune evasion, making it a candidate for cancer immunotherapy studies. However, comprehensive mechanistic insights and clinical validations are still lacking, underscoring the need for further research to clarify its pathophysiological roles and therapeutic potential.